Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
08:12am, Thursday, 13'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
06:00am, Thursday, 13'th Nov 2025
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
08:00am, Monday, 10'th Nov 2025
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
06:06pm, Monday, 08'th Sep 2025
The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
10:55am, Friday, 22'nd Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionab
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
11:44am, Wednesday, 13'th Aug 2025
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice Pres
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
09:15am, Wednesday, 13'th Aug 2025
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $4.08 per share versus the Zacks Consensus Estimate of a loss of $3.75. This compares to a loss of $5 per share a year ago.
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
07:00am, Wednesday, 13'th Aug 2025
CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
08:00am, Wednesday, 06'th Aug 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split
08:31am, Thursday, 24'th Jul 2025
CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)
Mersana Therapeutics to Present at Upcoming Investor Conferences
08:00am, Tuesday, 20'th May 2025
CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) t
Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript
10:06am, Thursday, 15'th May 2025
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communica
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
09:20am, Thursday, 15'th May 2025
In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of the first table. The Median
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
09:16am, Thursday, 15'th May 2025
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.16 per share a year ago.
